drugset
Drugs / E-EDV-D682
last change Jan 2026 re-read 3 minutes ago

E-EDV-D682

Other / unclassified targets EGFR via depletion

Developed for
pancreatic ductal adenocarcinoma
Investigated by
Engeneic Pty Limited · Herbert Irving Comprehensive Cancer Center

Trials 1

today NCT07049055 · Ph 1/2
202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07049055 Jan 2026 → Sep 2028 expected pancreatic ductal adenocarcinoma Engeneic Pty Limited Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2020-06-01 Engeneic Pty Limited Results Abstract accepted to the Annual Meeting of the American Society of Clinical Oncology 2020 engeneic.com ↗

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as E-EDV-D682 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07049055 ↗
Action Deplete “where it attaches to the surface of EGFR expressing cancer cells causing the cancer cells to die.” NCT07049055 ↗
Modality Other / unclassified “EDVs are bacterially derived nanocells 400 nm in diameter” NCT07049055 ↗
Route Intravenous “Doses of E-EDV-D682/GC in 3mL of 0.9% sodium chloride are administered intravenously over 10 seconds.” NCT07049055 ↗
Target EGFR “E-EDV-D682 packages a chemotherapeutic payload PNU159682 into the EDV which targets the epidermal growth factor (EGFR) on cancer cells via a BsAb.” NCT07049055 ↗